clinical trial

In April 2019 the Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).  We’re grateful to brave patients like Carol who participated in a clinical trial and helped make this treatment a reality for advanced RCC patients.   I have been retired for more than 5 years.  I have always been a person with a lot of energy.  In fact, I used to teach 3rd grade in an all boys school.  Energy needed there! In the fall of 2016, I began to have terrible night sweats, changing many times a night, and was just exhausted.  I went to my primary doctor who knows I’m not a complainer.  She could tell my lymph nodes were swollen and began doing tests. At first, lym...